In addition, we discuss the translational prospects of PYY-centered therapeutic strategies, either as monotherapy or as adjuncts to established incretin-based regimens, highlighting their promise in preserving β-cell reserve and optimizing long-term glycemic management in T2D. This evidence concerns the gene PYY and type 2 diabetes mellitus.